Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-15 · accession 0001819790-25-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-18 | 2025-03-15 | TARS | Neervannan Seshadri | COO | M - OptEx | — | +21.3K | 87.3K | +32% | — |
| DM | 2025-03-18 | 2025-03-15 | TARS | Neervannan Seshadri | COO | M - OptEx | $0.00 | -21.3K | 5,097 | -81% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-15 | M | A | 21,264 | — | 87,265 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). (F2) Includes 1,234 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024. |
| 2 | Derivative | Restricted Stock Units | 2025-03-15 | M | D | 8,148 | $0.00 | 16,296 | D | — · — to — | 8,148 Common Stock | (F3) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F5) RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. |
| 3 | Derivative | Restricted Stock Units | 2025-03-15 | M | D | 8,019 | $0.00 | 24,060 | D | — · — to — | 8,019 Common Stock | (F3) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F6) RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. |
| 4 | Derivative | Restricted Stock Units | 2025-03-15 | M | D | 5,097 | $0.00 | 5,097 | D | — · — to — | 5,097 Common Stock | (F3) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F4) RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. |